Navigation Links
MEDRAD(R) Revenues Grow 10 Percent in 2008
Date:3/26/2009

Highlights Include Possis Acquisition and Patient Care Innovations

WARRENDALE, Pa., March 26 /PRNewswire/ -- MEDRAD, INC.'s revenues grew to over $600 million in 2008, an increase of more than 10 percent over the previous year (excluding the effect of the Possis Medical, Inc. acquisition). A worldwide leading provider of diagnostic imaging and therapeutic medical devices, MEDRAD has achieved a double-digit annual revenue growth for over 10 years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

2008 business highlights include the acquisition of Possis Medical, award-winning product innovations and LEED certification for two new buildings.

"The Possis acquisition created the cornerstone of our vascular intervention strategy, and marks our renewed commitment to providing therapeutic solutions for improved patient care," said MEDRAD President and CEO John Friel. "We are not immune to the impact of a down economy, but there will always be a demand for improving patient outcomes with innovative, cost-efficient products."

MEDRAD acquired Possis Medical in April 2008, pairing Possis' leadership position in the thrombectomy market with MEDRAD's cardiovascular products and worldwide infrastructure. Possis develops, manufactures and markets pioneering medical devices for the large and growing cardiovascular and vascular treatment markets. The company's AngioJet(R) product is the world's leading mechanical thrombectomy system, with FDA approval to remove large and small clots from coronary arteries, coronary bypass grafts, and peripheral arteries and veins. This segment of MEDRAD's business is now known as MEDRAD Interventional/Possis.

MEDRAD also launched its Intego(TM) PET Infusion System in 2008. By automating and controlling Fluorodeoxyglucose (FDG) dosing and infusion, this innovative system minimizes the need to manually prepare and handle individual FDG doses, reducing potential radiation exposure to hospital personnel by more than 20 percent. Intego was named one of Medical Imaging Magazine's top eight most innovative products of the year.

Encouraged by the successful results of its P3T(TM) Cardiac personalized patient protocol software, MEDRAD expanded its clinical applications to include the diagnosis of pulmonary embolism. Achieving a diagnostic CT image for pulmonary embolism, without limitations, helps hospital and emergency departments with efficiency, patient care and cost savings.

MEDRAD received some significant recognitions over the past year:

  • The Heilman Center plant was selected as the nation's top manufacturing facility by the Association of Manufacturing Excellence
  • MEDRAD's field service team was awarded the Service Leader of the Year Award at the 2008 national Field Service 2008 Conference
  • The XDS(TM) Extravasation Detector received a 2008 Medical Design Excellence Award(R) (MDEA). The XDS employs a technology that aids in the detection of leaking intravenous contrast media from the injection site into surrounding tissue during computed tomography (CT) diagnostic studies.
  • MEDRAD's two newest facilities achieved LEED(R) (Leadership in Energy and Environmental Design) certification for new construction from the U.S. Green Building Council. Certification is based on the number of credits received across several categories, including sustainable site development, water efficiency and energy efficiency.

About MEDRAD, INC.

MEDRAD, INC. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the safe treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD's total 2008 revenues were over $600 million. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a business of Bayer Medical Care. More company information is available at www.medrad.com.

Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Bayer's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Bayer undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE MEDRAD, INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD(R) Revenues Grow 10 Percent in 2007
2. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
3. Nyer Medical Group, Inc. Reports Revenues of $19.0 Million for the Quarter Ended December 31, 2008
4. Volcano Reports Full Year Revenues Increase 31 Percent
5. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
6. Thoratec Reports 34 Percent Increase in 2008 Revenues
7. Somanetics Reports Record Net Revenues and Income Before Income Taxes for Fourth Quarter and Fiscal 2008
8. PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate
9. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. CorVel Announces Second Quarter Revenues and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology: